Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

• potassium channels are the most prevalent and diverse, being found in a variety of animal cells such as nervous, muscular, glandular, immune, reproductive, and epithelial tissue. These channels allow the flow of potassium in and/or out of the cell under certain conditions. These channels are regulated, e.g., by calcium sensitivity, voltage-gating, second messengers, extracellular ligands, and ATP-sensitivity.
• the small conductance calcium-activated potassium channels are a subfamily of Ca 2+ -activated K + channels and the SK channel family contains 4 members - SKI, SK2, SK3, and SK4 (often referred to as intermediate conductance).
• the physiological roles of the SK channels have been especially studied in the nervous system, where for example they are key regulators of neuronal excitability and of neurotransmitter release, and in smooth muscle, where they are crucial in modulating the tone of vascular, broncho- tracheal, urethral, uterine or gastro-intestinal musculature.
• FIG. 1 is a diagram illustrating the effect of Compound 1 following oral (PO) dosing on harmaline induced tremor.
• FIG. 2 displays the efficacy and dose response of Compound 1 in percent motion power.
• FIG. 3 shows the effects of Compound 1 on Purkinje cell firing irregularity in ex vivo slices from SCA2 58Q transgenic mice.
• FIG. 4 shows the effects of Compound 1 on baseline ataxia in the EA2 Tottering mouse model.
• the terms "subject” and “patient” may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like).
• the subject is a human in need of treatment.
• the stereochemistry of a disclosed compound is named or depicted by structure
• the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to all of the other stereoisomers.
• Percent by weight pure relative to all of the other stereoisomers is the ratio of the weight of one stereoisiomer over the weight of the other stereoisomers.
• the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure.
• Percent optical purity by weight is the ratio of the weight of the enantiomer over the weight of the enantiomer plus the weight of its optical isomer.
• salts of the compounds refer to nontoxic "pharmaceutically acceptable salts.”
• Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
• Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, n-methyl-D-glucamine, L-lysine, L-arginine, ammonium, ethanolamine, piperazine and triethanolamine salts.
• Pharmaceutically acceptable acidic/anionic salts include, e.g., the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, carbonate, citrate, dihydrochloride, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, malate, maleate, malonate, mesylate, nitrate, salicylate, stearate, succinate, sulfate, tartrate, and tosylate.
• compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose- based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxy
• treatment refers to reversing, alleviating, reducing the likelihood of developing, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
• treatment may be administered after one or more symptoms have developed, i.e., therapeutic treatment.
• treatment may be administered in the absence of symptoms.
• treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors), i.e., prophylactic treatment. Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
• an effective amount or “therapeutically effective amount” includes an amount of a compound described herein that will elicit a biological or medical response of a subject.
• compounds and compositions described herein are useful in treating diseases and/or disorders associated with the activity of potassium channels.
• diseases and/or disorders include e.g., neurodegenerative and neurological conditions (e.g., Parkinson's disease, tremors, Alzheimer's disease, dementia, amyotrophic lateral sclerosis (ALS) ataxia, anxiety, depression, mood disorders, memory and attention deficits, bipolar disorder, psychosis, schizophrenia, traumatic brain injury, and narcolepsy), heart disease and related conditions (e.g., ischaemic heart disease, coronary heart disease, angina pectoris, and coronary artery spasms), metabolic disease and bladder diseases (e.g., bladder spasms, urinary incontinence, bladder outflow obstruction, gastrointestinal dysfunction, irritable bowel syndrome, and diabetes), withdrawal symptoms associated with termination of addiction, and other conditions associated with the modulation of potassium channels such as e.g., respiratory diseases, epilepsy, convulsions, seizures, absence seizures,
• the present disclosure also provides a method of modulating the activity of a potassium channel in a subject comprising the step of administering a compound described herein.
• the present disclosure provides a method of positively modulating a SK2 channel in a cell comprising the step of contacting the cell with a compound described herein.
• the provided compounds and compositions are used to treat tremors.
• Tremors include, but are not limited to rest, active, postural, kinetic, intention, task specific, and idiopathic tremors.
• the provided compounds and compositions are used to treat postural and active tremors. Examples of postural and/or active tremors include essential tremor, drug-induced parkinsonism, neuropathic tremor, and tremors induced from toxins (e.g., alcohol withdrawal or from exposure to heavy metals).
• the provided compounds and compositions are used to treat essential tremor.
• the present disclosure further provides a method of treating essential tremor in a subject comprising the step of administering a compound or pharmaceutically acceptable salt or composition described herein.
• Essential tremor is one of the most common neurological disorders, affecting -0.9% of the general population.
• Essential tremor is characterized by an action tremor of the upper limbs and, less commonly, the head, voice, and trunk.
• a family history of essential tremor can be identified in approximately half of patients, suggesting a genetic component. Drinking alcohol often temporarily reduces tremor.
• the present disclosure provides a method of treating a disease or condition selected from a neurodegenerative disease, dementia, heart disease, withdrawal symptoms associated with termination of addiction, metabolic disease, and bladder disease.
• a disease or condition selected from ataxia, dystonia, Parkinson's disease, ischemia, traumatic brain injury, amyotrophic lateral sclerosis, hypertension, atherosclerosis, diabetes,
• the present disclosure provides a method of treating ataxia. In some embodiments, the present disclosure provides a method of treating spinocerebellar ataxia. [0026]
• the present disclosure provides pharmaceutically acceptable compositions comprising a compound described herein; and a pharmaceutically acceptable carrier. These compositions can be used to treat one or more of the diseases and conditions described above.
• compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
• parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra- articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
• Liquid dosage forms, injectable preparations, solid dispersion forms, and dosage forms for topical or transdermal administration of a compound are included herein.
• provided compounds that may be combined with carrier materials to produce a composition in a single dosage form will vary depending upon the patient to be treated and the particular mode of administration. In some embodiments, provided
• compositions may be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the provided compound, such as e.g., 0.1 - 100 mg/kg body weight/day, can be administered to a patient receiving these compositions.
• a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the particular disease being treated.
• the amount of a provided compound in the composition will also depend upon the particular compound in the composition.
• 1H NMR exhibited, via integration, 3 proton resonances in the aromatic region and 1 broad resonance corresponding to the exchangeable proton at N-18.
• the aromatic protons were observed as two doublets and a singlet, indicating two adjacent protons, and one isolated aromatic proton.
• resonances corresponding to 20 protons were observed, showing 1 distinct singlet. Integration of these resonances corresponded to two upfield doublet-doublet resonances, one with a partially overlapping multiplet proton, and four downfield multiplets, two of which partially overlap.
• the upfield aliphatic multiplets are associated with the morpholine moiety of the structure.
• the downfield multiplets are split additionally by the proximity of CF 2 to these protons.
• 13 C NMR data revealed 14 separate carbon resonances and were generated from a decoupled 13 C carbon spectrum acquired at 25 °C in CDC1 3 .
• the 14 resonances are consistent with the structure of 1 in which four pairs of the 18 carbons are spectroscopic ally equivalent.
• One carbon resonance (C-12 at 77.05 ppm) was observed to be partially obscured by the CHCI 3 resonance in the spectrum.
• the presence of a carbon at this resonance was confirmed by collection of a 13 C spectrum in C 6 D6; a resonance at 79.7 ppm was observed without interference from the solvent peak, in addition to all other resonances observed.
• Each of the triplets observed are consistent with F2 substitution at C-22, and decreasing coupling constant with respect to fluorine as the number of intervening bonds increase.
• reaction was heated to 60 °C, and completion of reaction was determined by TLC and UPLC. After 5 h, the reaction mixture was concentrated under reduced pressure and the residue was diluted with ethyl acetate, washed with water, and washed with brine solution.
• the reaction mixture was cooled to room temperature, filtered, and the solid was washed with ethyl acetate (500 mL). The filtrate was washed with water (2 x 100 mL), brine (100 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (60-120 silica gel) eluted with 15% EtOAc in hexane.
• reaction mixture was degassed using argon gas for 5-10 min, followed by addition of bis(triphenylphosphine)palladium(II) dichloride (0.2 g, 0.28 mmol, 0.02 eq).
• the reaction mixture was sealed and heated at 80 °C for 16 h (completion of reaction was determined by LCMS) and cooled to room temperature.
• the reaction mixture was diluted with water (300 mL) and extracted with ethyl acetate (2 x 150 mL). The combined organics were dried over sodium sulfate, filtered, and evaporated to afford a crude product as a light brown sticky solid.
• reaction mixture was concentrated to remove acetone, diluted with ice cold water (100 mL), basified with saturated sodium by carbonate solution, and extracted with ethyl acetate (2 x 100 mL). The combined organics were dried over sodium sulfate, filtered, and evaporated under reduced pressure to afford a crude product as a light brown sticky solid.
• reaction mixture was slowly warmed to rt and stirred at same temperature for 6 hours. The completion of reaction was determined by TLC and UPLC. The reaction mixture was concentrated and the resulting residue was quenched with 10% saturated sodium bicarbonate solution, extracted with ethyl acetate (2x100 mL), and concentrated under reduced pressure to afford crude product. The crude product was purified through column chromatography using 60-120 silica gel, ethyl acetate-pet ether as solvent system. The resulting solid was dried under vacuum to afford 2- (3-cyclopropyl-lH-pyrazol-l-yl)-N-(4,4-difluorocyclohexyl)-6-morpholinopyrimidin-4- amine 7 (0.73g, 90%).
• a compound is defined to be an SK Positive Allosteric Modulator (PAM) if the compound increases current in this assay, for example, if the SCioo value of the compound is less than or equal to 10 ⁇ as determined by this assay.
• the SCioo value is defined to be the concentration of compound that increases the basal current by 100%.
• the signal was filtered with a 128-ms unweighted moving average filter, and events with amplitudes > 0.5 V and lasting > 300 ms in duration were counted as a tremor event.
• Data were analyzed in one-minute bins over the course of the test and presented as the sum of tremor events over the entire 60 minute test. As shown by FIG. 1, significant inhibition of tremors was observed at a dose of 30 mg/Kg Compound I.
• %MP percent Motion Power
• C FB is the amount of free compound not complexed with protein and therefore free to interact with the SK2 channel (Table 1, "Calculated Free Brain Concentration”).
• BFF is average free fraction of compound as measured by equilibrium dialysis in separate experiments (1 uM test concentration incubated in 10% rat brain tissue homogenate for 5 hours at 37 C C) (Table 1, "Brain Free Fraction”). Free drug in brain available to interact with SK2 channels (C FB) is arrived at by multiplying the measured total brain level (C MB ) by the average free fraction (BFF).
• %SK2 SCioo C FB /SK2 SCioo 100, where SK2 SCioo (Table 1, "SK2 SCioo") is the measured value of potency of the compound on SK2 channels and %SK2 SCioo (Table 1, "%SK2 SCioo") is the free brain concentration (C FB ) normalized to SK2 SCioo- Values are given in Table 1.
• Compound 1 has demonstrated efficacy in validated animal models of hereditary ataxia (EA2) and ET (harmaline-induced tremor). To test whether Compound 1 can alleviate ataxia in a disease model, it was evaluated in the EA2 "Tottering" mouse model. These mice display a basal ataxia that arises from irregularity in Purkinje cell pacemaker firing due to a loss-of-function mutation in P/Q Ca 2+ channels (the same protein that is mutated in SCA6), which causes Episodic Ataxia 2 (EA2). Animals were assessed in the parallel rod floor apparatus which automatically counts the number of times the animal's foot slips through the evenly spaced metal rods and the total distance the animal travels.
• EA2 hereditary ataxia
• ET aline-induced tremor
• Ataxia Ratio Baseline ataxia was then expressed as the Ataxia Ratio, which is the total number of foot slips divided by the total distance the animal travels in centimeters.
• the increase in Ataxia Ratio between wild-type and EA2 mice is illustrated in FIG. 4.
• Aqueous solubility (kinetic solubility) tests of the compounds were performed in phosphate buffer saline (pH 7.4) measured by shake-flask method.
• DMSO stock solution of test compound is added to buffer followed by equilibration (shaking), filtration and determination of soluble amount by HPLC-UV Conditions used in the assay are summarized below. Results are shown in Table 2 and Table 3.
• Aqueous buffer 0.05M Phosphate Buffer System pH 7.4
• HPLC-UV Reference compounds Caffeine (high solubility) and Diethylstilbestrol (low solubility)
• test compound is incubated with liver microsomes in the presence of NADPH for 2 time points at 37°C. At the end of incubation, reaction is quenched with acetonitrile containing internal standard and the parent compound remaining is determined by LC-MS/MS. Conditions used in the assay are summarized below. Results are shown in Table 2.
• Liver microsome protein concentration in assay 0.5mg/ml
• Test drug (Inhibitor) Concentration 8 different concentrations ( ⁇ to 0.005 ⁇ )
• hERG cardiac potassium channel hERG assay.
• hERG is responsible for a rapid delayed rectifier current ( ⁇ ) in human ventricles.
• Inhibition of I & is the most common cause of cardiac action potential prolongation by non-cardiac drugs. See e.g., Brown, A.M. and Rampe, D. (2000). Drug-induced long QT syndrome: is HERG the root of all evil? Pharmaceutical News 7, 15-20.
• HEK-293 cells were stably transfected with hERG cDNA. Stable transfectants were selected by coexpression with the G418-resistance gene incorporated into the expression plasmid. Selection pressure was maintained by including G418 in the culture medium.
• Cells were cultured in Dulbecco' s Modified Eagle Medium / Nutrient Mixture F-12 (D-MEM/F-12) supplemented with 10% fetal bovine serum, 100 U/mL penicillin G sodium, 100 ⁇ g/mL streptomycin sulfate and 500 ⁇ g/mL G418. Cell culture records are kept on file at Charles River Laboratories.
• Onset and steady state inhibition of hERG current was measured using a pulse pattern with fixed amplitudes (conditioning prepulse: +20 mV for 2 s; test pulse: -50 mV for 2 s) repeated at 10 s intervals, from a holding potential of -80 mV. Peak tail current was measured during the 2 s step to -50 mV.
• Rat strain/sex Sprague Dawley/Male Age / body weight: 6 to 8 weeks/ 250-300gms
• Dosing volume Intravenous (2ml/kg) & Oral (lOml/kg)
• Formulation vehicles Standard formulations or suggested by Sponsor
• Dose levels IV & Oral: lmg/kg; intravenous & lOmg/kg; oral or as suggested
• Anti-coagulant 0.2% K2 EDTA
• SC 100 Concentration that produces doubling of channel current
• Compound 1 also has better solubility, higher BFF, higher microsomal stability, and greater oral bioavailability than Comparator A.
• An overall improvement in BFF and solubility over Comparator A and phenyl derivative Comparator C was also demonstrated across the compounds described herein as shown in Table 3. Compound 1 is reproduced from above for ease of comparison.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Addiction (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Neurosurgery (AREA)
• Psychiatry (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pyridine Compounds (AREA)
• Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)

Priority Applications (23)

Applications Claiming Priority (2)

Publications (1)

Family

ID=61188924

Family Applications (1)

Country Status (30)

Cited By (1)

Families Citing this family (3)

Citations (2)

Family Cites Families (188)

• 2018
  • 2018-01-23 CU CU2019000066A patent/CU24560B1/es unknown
  • 2018-01-23 US US15/877,910 patent/US9975886B1/en active Active
  • 2018-01-23 BR BR112019014814-0A patent/BR112019014814B1/pt active IP Right Grant
  • 2018-01-23 DK DK18704122.3T patent/DK3571193T3/da active
  • 2018-01-23 SG SG11201905893WA patent/SG11201905893WA/en unknown
  • 2018-01-23 EA EA201991488A patent/EA036668B1/ru unknown
  • 2018-01-23 HU HUE18704122A patent/HUE057710T2/hu unknown
  • 2018-01-23 PT PT187041223T patent/PT3571193T/pt unknown
  • 2018-01-23 HR HRP20220079TT patent/HRP20220079T1/hr unknown
  • 2018-01-23 PL PL18704122T patent/PL3571193T3/pl unknown
  • 2018-01-23 SI SI201830559T patent/SI3571193T1/sl unknown
  • 2018-01-23 UA UAA201908610A patent/UA123810C2/uk unknown
  • 2018-01-23 WO PCT/US2018/014792 patent/WO2018136917A1/en not_active Ceased
  • 2018-01-23 CN CN201880007979.1A patent/CN110198935B/zh active Active
  • 2018-01-23 MY MYPI2019003912A patent/MY195123A/en unknown
  • 2018-01-23 JP JP2019539923A patent/JP6997197B2/ja active Active
  • 2018-01-23 KR KR1020197024269A patent/KR102664772B1/ko active Active
  • 2018-01-23 LT LTEPPCT/US2018/014792T patent/LT3571193T/lt unknown
  • 2018-01-23 EP EP18704122.3A patent/EP3571193B1/en active Active
  • 2018-01-23 TW TW107102410A patent/TWI751271B/zh active
  • 2018-01-23 AR ARP180100148A patent/AR110770A1/es active IP Right Grant
  • 2018-01-23 MX MX2019008682A patent/MX376080B/es active IP Right Grant
  • 2018-01-23 ES ES18704122T patent/ES2906078T3/es active Active
  • 2018-01-23 RS RS20220119A patent/RS62899B1/sr unknown
  • 2018-03-28 US US15/938,292 patent/US10351553B2/en active Active
• 2019
  • 2019-06-04 US US16/431,212 patent/US10717728B2/en active Active
  • 2019-07-08 ZA ZA2019/04458A patent/ZA201904458B/en unknown
  • 2019-07-09 IL IL267954A patent/IL267954B/en unknown
  • 2019-07-19 CL CL2019002031A patent/CL2019002031A1/es unknown
  • 2019-07-22 PH PH12019501678A patent/PH12019501678A1/en unknown
  • 2019-08-22 CO CONC2019/0009060A patent/CO2019009060A2/es unknown
• 2021
  • 2021-01-15 US US17/150,230 patent/US20210380571A1/en not_active Abandoned
• 2022
  • 2022-03-01 CY CY20221100176T patent/CY1125463T1/el unknown

Patent Citations (2)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events